Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators.
Mark D, Talley J, Topol E, Bowman L, Lam L, Anderson K, Jollis J, Cleman M, Lee K, Aversano T, Untereker W, Davidson-Ray L, Califf R. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation 1996, 94: 629-35. PMID: 8772681, DOI: 10.1161/01.cir.94.4.629.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplastyAntibodies, MonoclonalAnticoagulantsAspirinBlood TransfusionCosts and Cost AnalysisDouble-Blind MethodFemaleHeparinHumansImmunoglobulin Fab FragmentsInfusions, IntravenousInjections, IntravenousMaleMiddle AgedMyocardial IschemiaPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexRecurrenceStentsTreatment OutcomeUnited StatesConceptsHigh-risk coronary angioplastyC7E3 FabIschemic eventsCoronary angioplastyInitial hospitalizationPlatelet glycoprotein IIb/IIIa inhibitionGlycoprotein IIb/IIIa inhibitionIIb/IIIa inhibitionAggressive platelet inhibitionBaseline medical costsIschemic end pointsReduced ischemic eventsAcute ischemic eventsCost of therapyEPIC trialMajor bleedingBleeding episodesIschemic complicationsStandard carePlatelet inhibitionHospitalization ratesReceptor antibodiesHospital costsMedical costsMedicare fee